Sugi Predict

Sugi Predict / Compounds / SCHEMBL115698

SCHEMBL115698

SCHEMBL115698

CC(C)(C)OC(=O)N1CCC[C@H]1CCO

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 2/20 0.49
▸ HSD17B10 Q99714 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ PDE8B O95263 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ OPRD1 P41143 1/20 0.41
▸ CHEK2 O96017 1/20 0.41
▸ TSHR P16473 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639097 1.00 ATM (0.49) ATMHSD17B10SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL3420227 1.00 ATM (0.49) ATMHSD17B10SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL2354644 0.95 ATM (0.51) ATMHSD17B10SMN1; SMN2ALDH1A1PDE8B
SCHEMBL1551631 0.95 ATM (0.51) ATMHSD17B10SMN1; SMN2ALDH1A1PDE8B
SCHEMBL2345014 0.95 ATM (0.51) ATMHSD17B10SMN1; SMN2ALDH1A1PDE8B
SCHEMBL3847564 0.94 ATM (0.50) ATMHSD17B10SMN1; SMN2ALDH1A1PDE8B
SCHEMBL3842356 0.94 ATM (0.50) ATMHSD17B10SMN1; SMN2ALDH1A1PDE8B
SCHEMBL6337357 0.91 HSD17B10 (0.45) ATMHSD17B10SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL6337962 0.91 HSD17B10 (0.45) ATMHSD17B10SMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL6337359 0.91 HSD17B10 (0.45) ATMHSD17B10SMN1; SMN2ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 — — US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 — — WO disclosed
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
US-12134609-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-11-05 — — US disclosed
US-20240317775-A1 H4 Antagonist Compounds NXERA PHARMA UK LIMITED (GB) 2024-09-26 — — US disclosed
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-03-21 — — US disclosed
US-11873291-B2 Quinoline cGAS antagonist compounds IMMUNESENSOR THERAPEUTICS, INC. (US) 2024-01-16 — — US disclosed
EP-4259637-A1 H4 ANTAGONIST COMPOUNDS Heptares Therapeutics Limited (GB) 2023-10-18 — — EP disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 — — EP disclosed
US-11718638-B2 Compounds, compositions and methods for synthesis WAVE LIFE SCIENCES LTD. (SG) 2023-08-08 — — US disclosed
US-20120214790-A1 N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. 2012-08-23 — — US disclosed
US-20120058989-A1 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2012-03-08 — — US disclosed
US-20120058989-A1 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2012-03-08 — — US disclosed
US-20120058989-A1 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2012-03-08 — — US disclosed
WO-2011111875-A1 N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 — — WO disclosed
EP-2250171-A2 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS Achaogen, Inc. (US) 2010-11-17 — — EP disclosed
WO-2009137130-A2 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2009-11-12 — — WO disclosed
WO-2009137130-A2 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS ACHAOGEN, INC. (US) 2009-11-12 — — WO disclosed
US-5948793-A 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling neurotransmitter release ABBOTT LABORATORIES (US) 1999-09-07 — — US disclosed
US-5914328-A CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS ABBOTT LABORATORIES (US) 1999-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317775-A1 H4 Antagonist Compounds HRH4, HRH3, H1-4 ATM 3292/4885HSD17B10 1833/4885SMN1; SMN2 3531/4885
US-11718638-B2 Compounds, compositions and methods for synthesis ALKBH1, DUT, RNGTT ATM 4229/4885HSD17B10 4428/4885SMN1; SMN2 524/4885
US-20240092760-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS ATM 234/4885HSD17B10 2690/4885SMN1; SMN2 2633/4885
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 ATM 235/4885HSD17B10 1160/4885SMN1; SMN2 4309/4885
US-11873291-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ATM 234/4885HSD17B10 2690/4885SMN1; SMN2 2633/4885
US-12134609-B2 Quinoline cGAS antagonist compounds CGAS, GLS2, GLS ATM 234/4885HSD17B10 2690/4885SMN1; SMN2 2633/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS ATM 835/4885HSD17B10 3549/4885SMN1; SMN2 1576/4885
US-20120058989-A1 ANTIBACTERIAL FLUOROQUINOLONE ANALOGS RECQL, BLVRB, NQO2 ATM 3737/4885HSD17B10 1844/4885SMN1; SMN2 3896/4885
US-20120214790-A1 N-ACYL CYCLIC AMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF GRIN2C, GRIN2A, GRIN2B ATM 2325/4885HSD17B10 340/4885SMN1; SMN2 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.